ACCO Brands Corporation Declares Quarterly Dividend
LAKE ZURICH, Ill.–(BUSINESS WIRE)–ACCO Brands Corporation (NYSE: ACCO) today announced that its board of directors has declared a quarterly cash dividend... Read more.
Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development
Dr. Massacesi will join BMS August 1 and serve on the Executive Leadership Team Samit Hirawat, M.D., Executive Vice President, to step down from his role on August... Read more.
Sensient Technologies Corporation Reports Results for the Quarter Ended June 30, 2025
MILWAUKEE–(BUSINESS WIRE)–Sensient Technologies Corporation (NYSE: SXT), a leading provider of flavors and colors for the food, pharmaceutical, and personal... Read more.
Gorman-Rupp Company Declares Cash Dividend
MANSFIELD, Ohio–(BUSINESS WIRE)–#DIVIDENDS–The Board of Directors of The Gorman-Rupp Company (NYSE: GRC) has declared a quarterly cash dividend... Read more.
Booz Allen Hamilton Announces First Quarter Fiscal Year 2026 Results
MCLEAN, Va.–(BUSINESS WIRE)–$BAH #earnings–Booz Allen Hamilton Holding Corporation (NYSE: BAH), the parent company of advanced technology company... Read more.
Gorman-Rupp Reports Second Quarter 2025 Financial Results
MANSFIELD, Ohio–(BUSINESS WIRE)–#EARNINGS–The Gorman-Rupp Company (NYSE: GRC) reports financial results for the second quarter ended June 30, 2025.... Read more.
GrafTech Reports Second Quarter 2025 Results
Continuing to Deliver on Key Commercial, Operational and Financial Objectives BROOKLYN HEIGHTS, Ohio–(BUSINESS WIRE)–GrafTech International Ltd. (NYSE:... Read more.
Thyroid Gland Disorders Diagnostics and Treatment Market Analysis Report 2025 | Revenue Data from 2022 to 2024, Estimates for 2025, and Projected CAGRs Through 2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Thyroid Gland Disorders: Diagnostics and Treatment Market” report has been added to ResearchAndMarkets.com’s... Read more.
Carter’s, Inc. Reports Second Quarter Fiscal 2025 Results
Net sales $585 million vs. $564 million in Q2 2024; growth of 4% Diluted EPS $0.01 vs. $0.76 in Q2 2024; adjusted diluted EPS $0.17 vs. $0.76 in Q2 2024 Returned... Read more.
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing... Read more.